151 related articles for article (PubMed ID: 20970309)
1. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
[TBL] [Abstract][Full Text] [Related]
2. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
[TBL] [Abstract][Full Text] [Related]
3. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells.
Hashimoto O; Shimizu K; Semba S; Chiba S; Ku Y; Yokozaki H; Hori Y
Pathobiology; 2011; 78(4):181-92. PubMed ID: 21778785
[TBL] [Abstract][Full Text] [Related]
5. [Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy].
Cai C; Wang J; Zhong Z; Dai Z; Wang Q; Dong W; Shi H; Liu Q; DU J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):36-43. PubMed ID: 28436629
[TBL] [Abstract][Full Text] [Related]
6. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Morimoto Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2010 Aug; 24(2):345-50. PubMed ID: 20596619
[TBL] [Abstract][Full Text] [Related]
8. CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1α (HIF-1α).
Sun C; Song H; Zhang H; Hou C; Zhai T; Huang L; Zhang L
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1619-24. PubMed ID: 22614155
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.
Hashimoto K; Aoyagi K; Isobe T; Kouhuji K; Shirouzu K
Gastric Cancer; 2014 Jan; 17(1):97-106. PubMed ID: 23558457
[TBL] [Abstract][Full Text] [Related]
10. CD133(+)HIF-1α(-) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer.
Tachikawa Y; Kawai K; Ozaki K; Nozawa H; Sasaki K; Murono K; Emoto S; Kishikawa J; Yokoyama Y; Abe S; Nagai Y; Anzai H; Sonoda H; Ishihara S
Anticancer Res; 2022 Apr; 42(4):2033-2043. PubMed ID: 35347026
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
12. Expression of hypoxia-inducible factor 1α predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally advanced rectal cancer.
Shioya M; Takahashi T; Ishikawa H; Sakurai H; Ebara T; Suzuki Y; Saitoh J; Ohno T; Asao T; Kuwano H; Nakano T
J Radiat Res; 2011; 52(6):821-7. PubMed ID: 22104271
[TBL] [Abstract][Full Text] [Related]
13. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.
Matsumoto K; Arao T; Tanaka K; Kaneda H; Kudo K; Fujita Y; Tamura D; Aomatsu K; Tamura T; Yamada Y; Saijo N; Nishio K
Cancer Res; 2009 Sep; 69(18):7160-4. PubMed ID: 19738050
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia.
Zhu H; Wang D; Zhang L; Xie X; Wu Y; Liu Y; Shao G; Su Z
Oncol Rep; 2014 Sep; 32(3):935-42. PubMed ID: 24994549
[TBL] [Abstract][Full Text] [Related]
17. Immunohistological expression of HIF-1α, GLUT-1, Bcl-2 and Ki-67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer.
Havelund BM; Sørensen FB; Pløen J; Lindebjerg J; Spindler KL; Jakobsen A
APMIS; 2013 Feb; 121(2):127-38. PubMed ID: 23030583
[TBL] [Abstract][Full Text] [Related]
18. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Inoue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2010 Aug; 17(8):2051-8. PubMed ID: 20177796
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
[TBL] [Abstract][Full Text] [Related]
20. hypoxia-inducible factors activate CD133 promoter through ETS family transcription factors.
Ohnishi S; Maehara O; Nakagawa K; Kameya A; Otaki K; Fujita H; Higashi R; Takagi K; Asaka M; Sakamoto N; Kobayashi M; Takeda H
PLoS One; 2013; 8(6):e66255. PubMed ID: 23840432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
